Recreational cannabinoid use: The hazards behind the “high”

,; ,

Applied Evidence

Recreational cannabinoid use: The hazards behind the “high”

J Fam Pract. 2016 November;65(11):770-773,778-779

PDF Download

References

1. Pew Research Center. 6 facts about marijuana. Available at: http://www.pewresearch.org/fact-tank/2015/04/14/6-facts-about-marijuana/. Accessed September 27, 2016.

2. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. HHS Pub # (SMA) 14-4863. 2014. Available at: http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. Accessed September 27, 2015.

3. Johnston LD, O’Malley PM, Miech RA, et al. Monitoring the Future National Survey on Drug Use 1975-2015. Available at: http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2015.pdf. Accessed September 23, 2015.

4. Metts J, Wright S, Sundaram J, et al. Medical marijuana: a treatment worth trying? J Fam Pract. 2016;65:178-185.

5. Governing the states and localities. State marijuana laws map. Available at: http://www.governing.com/gov-data/state-marijuana-laws-map-medical-recreational.html. Accessed October 12, 2016.

6. US Drug Enforcement Administration. Drug scheduling. Available at: https://www.dea.gov/druginfo/ds.shtml. Accessed October 12, 2016.

7. El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of Δ⁹-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010;95:434-442.

8. Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction. 2012;107:1404-1417.

9. Gruber AJ, Pope HG, Hudson JI, et al. Attributes of long-term heavy cannabis users: a case-control study. Psychol Med. 2003;33:1415-1422.

10. Palamar JJ, Fenstermaker M, Kamboukos D, et al. Adverse psychosocial outcomes associated with drug use among US high school seniors: a comparison of alcohol and marijuana. Am J Drug Alcohol Abuse. 2014;40:438-446.

11. Zwerling C, Ryan J, Orav EJ. The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA. 1990;264:2639-2643.

12. Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction. 2002;97:1123-1135.

13. Bell C, Slim J, Flaten HK, et al. Butane hash oil burns associated with marijuana liberalization in Colorado. J Med Toxicol. 2015;11:422-425.

14. Huang DYC, Lanza HI, Anglin MD. Association between adolescent substance use and obesity in young adulthood: a group-based dual trajectory analysis. Addict Behav. 2013;38:2653-2660.

15. Rajavashisth TB, Shaheen M, Norris KC, et al. Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open. 2012;2:e000494.

16. Cho CM, Hirsch R, Johnstone S. General and oral health implications of cannabis use. Aust Dent J. 2005;50:70-74.

17. Gorzalka BB, Hill MN, Chang SC. Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Horm Behav. 2010;58:91-99.

18. Desbois AC, Cacoub P. Cannabis-associated arterial disease. Ann Vasc Surg. 2013;27:996-1005.

19. Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350:59-62.

20. Tuv SS, Strand MC, Karinen R, et al. Effect and occurrence of synthetic cannabinoids. Tidsskr Nor Laegeforen. 2012;132:2285-2288.

21. Wallace EA, Andrews SE, Garmany CL, et al. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011;104:659-964.

22. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: considerations of the literature. Respirology. 2014;19:655-662.

23. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years: The Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA. 2012;307:173-181.

24. Verweij PE, Kerremans JJ, Vos A, et al. Fungal contamination of tobacco and marijuana. JAMA. 2000;284:2875.

25. Office of Environmental Health Hazard Assessment. Evidence on the carcinogenicity of marijuana smoke. August 2009. Available at: http://oehha.ca.gov/media/downloads/crnr/finalmjsmokehid.pdf. Accessed September 5, 2015.

26. Stone D. Cannabis, pesticides and conflicting laws: the dilemma for legalized States and implications for public health. Regul Toxicol Pharmacol. 2014;69:284-288.

27. Hashibe M, Straif K, Tashkin DP, et al. Epidemiologic review of marijuana and cancer risk. Alcohol. 2005;35:265-275.

28. Liang C, McClean MD, Marsit C, et al. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009;2:759-768.

29. Thomas AA, Wallner LP, Quinn VP, et al. Association between cannabis use and the risk of bladder cancer: results from the California Men’s Health Study. Urology. 2015;85:388-392.

30. Holly EA, Lele C, Bracci PM, et al. Case-control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay area, California. Am J Epidemiol. 1999;150:375-389.

31. Massi P, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75:303-312.

32. Ashbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344:e536.

33.Barrio G, Jimenez-Mejias E, Pulido J, et al. Association between cannabis use and non-traffic injuries. Accid Anal Prev. 2012;47:172-176.

34. MacDonald S, Hall W, Roman P, et al. Testing for cannabis in the work-place: a review of the evidence. Addiction. 2010;105:408-416.

35. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18:185-193.

36. Ramaekers JG, Berghaus G, van Laar M, et al. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004;73:109-119.

37. Menetrey A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoid levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Δ9-THC. J Anal Toxicol. 2005;29:327-338.

38. Raemakers JG, Kaurert G, van Ruitenbeek P, et al. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31:2296-2303.

39. Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med. 1991;62:221-227.

40. Calabria B, Degenhardt L, Hall W, et al. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29:318-330.

41. Colorado Department of Public Health and Environment. Monitoring health concerns related to marijuana in Colorado: 2014. Changes in marijuana use patterns, systematic literature review, and possible marijuana-related health effects. Available at: http://www2.cde.state.co.us/artemis/hemonos/he1282m332015internet/he1282m332015internet01.pdf. Accessed September 5, 2015.

42. Behnke M, Smith VC, Committee on Substance Abuse, Committee on Fetus and Newborn. Perinatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131:e1009-1024.

43. Batalla A, Bhattacharyya S, Yücel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8:e55821.

44. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1-8.

45. Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of cannabis on cognition in patients with multiple sclerosis: a psychometric and MRI study. Neurology. 2014;82:1879-1887.

46. Bartholomew J, Holroyd S, Heffernan TM. Does cannabis use affect prospective memory in young adults? J Psychopharmacol. 2010;24:241-246.

47. Copeland J, Rooke S, Swift W. Changes in cannabis use among young people: impact on mental health. Curr Opin Psychiatry. 2013;26:325-329.

48. Ari M, Sahpolat M, Kokacya H, et al. Amotivational syndrome: less known and diagnosed as a clinical. J Mood Disord. 2015;5:31-35.

49. Zvolensky MJ, Cougle JR, Johnson KA, et al. Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol. 2010;18(2):129-134.

50. Yarnell S. The use of medicinal marijuana for posttraumatic stress disorder: a review of the current literature. Prim Care Companion CNS Disord. 2015;17(3).

51. Le Bec PY, Fatséas M, Denis C, et al. Cannabis and psychosis: search of a causal link through a critical and systematic review. Encephale. 2009;35:377-385.

52. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19-27.

53. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011:115:120-130.

54. Degenhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 2010;108:84-97.

55. Vandrey RG, Budney AJ, Hughes JR, et al. A within subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend. 2008;92:48-54.

56.Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4:4-16.

57. Turner SD, Spithoff S, Kahan M. Approach to cannabis use disorder in primary care: focus on youth and other high-risk users. Can Fam Phys. 2014;60:801-808.

58. Piontek D, Kraus L, Klempova D. Short scales to assess cannabis-related problems: a review of psychometric properties. Subst Abuse Treat Prev Policy. 2008;3:25.

59. Saitz R, Palfai TPA, Cheng DM, et al. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014;312:502-513.

60. McLellan AT, Lewis DC, O’Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.

Other validated screening tools include the Severity of Dependence Scale, the Cannabis Abuse Screening Test, and the Problematic Use of Marijuana.⁵⁸

Counsel patients about possible adverse effects and inform them there is no evidence that recreational marijuana or synthetic cannabinoids can be used safely over time. Consider medical use requests only if there is a favorable risk/benefit balance, other recognized treatment options have been exhausted, and you have a strong understanding of the use of cannabis in the medical condition being considered.⁴

Marijuana use is an independent causal risk factor for the development of psychosis—particularly in vulnerable youth.Since brief interventions using motivational interviewing to reduce or eliminate recreational use have not been found to be effective,⁵⁹ referral to an addiction specialist may be indicated. If a diagnosis of cannabis use disorder is established, then abstinence from addiction-prone substances including marijuana, programs like Marijuana Anonymous (Available at: https://www.marijuana-anonymous.org/), and individualized addiction therapy scaled to the severity of the condition can be effective.⁵⁶ Because psychiatric conditions frequently co-occur and complicate addiction,⁵³ they should be screened for and managed, as well.

Drug testing. Cannabis Use Disorder has significant relapse potential.⁶⁰ Abstinence and treatment adherence should be ascertained through regular follow-up that includes a clinical interview, exam, and body fluid drug testing. Point-of-care urine analysis for substances of potential addiction has limited utility. Definitive testing of urine with gas chromotography/mass spectrometry (GC/MS) or liquid chromatography (LC/MS-MS) can eliminate THC false-positives and false-negatives that can occur with point-of-care urine immunoassays. In addition, GCMS and LC/MS-MS can identify synthetic cannabinoids; in-office immunoassays cannot.

If the patient relapses, subsequent medical care should be coordinated with an addiction specialist with the goal of helping the patient to abstain from cannabis.

CORRESPONDENCE
Steven Wright, MD, FAAFP, 5325 Ridge Trail, Littleton, CO 80123; sleighwright@gmail.com.